文献速递肝病

艾尔巴韦-格拉瑞韦在慢性丙型肝炎患者中的真实世界应用:来自TRIO网络的回顾性分析

Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network.
PubMed 文献 · Aliment Pharmacol Ther · 2018-04-17

该回顾性队列研究评估了2016年美国470例接受艾尔巴韦-格拉瑞韦(联合或不联合利巴韦林)治疗的慢性丙型肝炎病毒(HCV)基因1或4型成人患者的应用与结局,主要终点为符合方案人群的治疗结束后12周持续病毒学应答(SVR12)。结果显示,基因1型符合方案SVR12为99%(396/402),基因4型为95%(21/22);在4期或5期慢性肾病患者中,99%(113/114)达到SVR12。艾尔巴韦-格拉瑞韦高度有效,且在该2016年队列中主要用于基因1型患者,以12周无利巴韦林方案为主。

要点

  • 基因1型符合方案SVR12为99%(396/402),基因4型为95%(21/22)。
  • 4期或5期慢性肾病患者中99%(113/114)达到SVR12。
  • 全样本单因素分析中,治疗时长(P=0.001)、治疗经历(P=0.016)和肝硬化状态(P=0.001)与符合方案SVR12显著相关。

核心结论

  • 艾尔巴韦-格拉瑞韦高度有效,在该2016年队列中主要用于HCV基因1型患者,以12周无利巴韦林方案为主。

研究设计与样本

  • 回顾性队列研究,纳入2016年接受艾尔巴韦-格拉瑞韦(联合或不联合利巴韦林)治疗的慢性HCV基因1或4型成人患者470例,数据来自医疗服务提供者和专业药房。

主要发现

  • 95%的患者为HCV基因1型感染,80%(373/468)为初治患者,70%(327/468)无肝硬化,73%在社区诊所接受治疗,89%接受12周疗程。
  • 符合方案SVR12:基因1型99%(396/402),基因4型95%(21/22);4期或5期慢性肾病患者99%(113/114)。
  • 全样本单因素分析中,与符合方案SVR12显著相关的变量为治疗时长(P=0.001)、治疗经历(P=0.016)和肝硬化状态(P=0.001);但在基因1型患者中无变量显著。
  • 意向性治疗SVR12:基因1型89%(396/447),基因4型91%(21/23)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Elbasvir-grazoprevir is indicated for chronic hepatitis C virus (HCV) genotypes 1 and 4. AIM: To evaluate the utilization and outcomes of chronic HCV patients treated with elbasvir-grazoprevir in the United States. METHODS: We conducted a retrospective cohort study of adults treated with elbasvir-grazoprevir with or without ribavirin for chronic HCV genotypes 1 or 4 infection. Data were collected from healthcare providers and specialty pharmacies through Innervation Platform, a proprietary, cloud-based disease management program from Trio Health. The primary endpoint was per protocol sustained virological response 12 weeks post-treatment (SVR12). RESULTS: Among 470 patients treated in 2016, 95% had HCV genotype 1 infection, 80% (373/468) were HCV treatment naïve and 70% (327/468) had non-cirrhotic disease. Almost 3 quarters (73%) of patients received care in community practices. The majority (89%) of patients received elbasvir-grazoprevir for 12 weeks. Per protocol SVR12 rates were 99% (396/402) for HCV genotype 1 and 95% (21/22) for HCV genotype 4. Among patients with Stage 4 or 5 chronic kidney diseases, 99% (113/114) achieved SVR12. In univariate analyses, variables significantly associated with per protocol SVR12 for the entire sample were therapy duration (P = 0.001), treatment experience (P = 0.016), and cirrhosis status (P = 0.001). However, among HCV genotype 1 patients, no variables were significant. Intent-to-treat SVR12 rates were 89% (396/447) for HCV genotype 1 and 91% (21/23) for HCV genotype 4. CONCLUSION: Elbasvir-grazoprevir is highly effective, and in this 2016 cohort, its use was predominantly in patients with HCV genotype 1 and as a 12-week therapy without ribavirin.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Flamm SL, Bacon B, Curry MP, et al. Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network. Aliment Pharmacol Ther. 2018. PMID: 29665097. doi:10.1111/apt.14635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。